01 Sep 2023 SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure Member news
29 Aug 2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus Member news
17 Jul 2023 argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy Member news
10 Jul 2023 Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure Member news
20 Jun 2023 argenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy Member news
05 Jun 2023 ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01 Member news
02 Jun 2023 Biotalys continues to demonstrate strength of first biocontrol in latest global field trials Member news
26 May 2023 Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
